Feb 6, 2013 6:12 AM PST
|
|
AMEX: INO Stock Quote
| Last Trade: | 0.7075 | Day's Range: | N/A - N/A | |
| Trade Time: | 4:00pm | 52wk Range: | 0.38 - 0.72 | |
| Change: | 0.00 (0.00%) | Volume: | 0 | |
| Prev Close: | 0.7075 | Avg Vol (3m): | 1,784,680 | |
| Open: | N/A | Market Cap: | 127.3M | |
| Bid: | N/A x N/A | P/E (ttm): | N/A | |
| Ask: | N/A x N/A | EPS (ttm): | -0.148 | |
| 1y Target Est: | 1.50 | Div & Yield: | 0.00 (N/A) |
AMEX: INO Overview
Inovio Pharmaceuticals, Inc., formerly Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of vaccines, called deoxyribonucleic acid (DNA) vaccines, focused on cancers and infectious diseases. The Company�s SynCon technology enables the design of universal DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio�s clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company�s HIV vaccines consist of candidates for HIV prevention as well as therapy or treatment.
Do you know of another great research resource for INO that belongs here? Please let us know and provide the URL.
